2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pain
11
Neoplasms
5
Cancer Pain
4
Pain, Postoperative
2
Malignant Female Reproductive System Neoplasm
2
Hematologic Neoplasms
2
Emergencies
2
Agnosia
2
Uterine Cervical Neoplasms
1
Tumor Surgery
1
Sarcoma
1
Rectal Neoplasms
1
Pulmonary Nodule
1
Prostatic Neoplasms
1
Postoperative Complications
1
Pancreatic Neoplasms
1
Pain, Intractable
1
Ovarian Neoplasms
1
Neuralgia
1
Neoplasm Metastasis
1
Mucositis
1
Lymphoma, Follicular
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Intraoperative Complications
1
Ileus
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Duodenal Neoplasms
1
Interventions
Sorafenib
68
Bevacizumab
44
Oxaliplatin
25
Doxorubicin
22
Gemcitabine
21
Fluorouracil
21
Radiosurgery
20
Nivolumab
19
durvalumab
18
Radiofrequency Ablation
18
pembrolizumab
17
lenvatinib
17
Cisplatin
17
Capecitabine
17
atezolizumab
14
Leucovorin
14
Hepatectomy
14
Radiotherapy
12
tremelimumab
10
Irinotecan
10
Drug Therapy
10
Cyclophosphamide
10
Carboplatin
10
Blood Specimen Collection
10
Ipilimumab
9
regorafenib
8
Liver Transplantation
8
Everolimus
8
Cryosurgery
8
Chemotherapy, Adjuvant
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
Hydromorphone
×
Clear all
NCT03715517
2026-02-05
SAFER-L
University of Manitoba
Phase NA
Recruiting
128 enrolled